Literature DB >> 11850875

The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents.

John H Powers, David B Ross, Erica Brittain, Renata Albrecht, Mark J Goldberger.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 11850875     DOI： 10.1086/339803

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

1.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

2.  Increasing consumption of MRSA-active drugs without increasing MRSA in German ICUs.

Authors:  Elisabeth Meyer; Frank Schwab; Barbara Schroeren-Boersch; Petra Gastmeier
Journal:  Intensive Care Med       Date:  2011-08-20       Impact factor: 17.440

3.  Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.

Authors:  Brad Spellberg; Roger J Lewis; Helen W Boucher; Eric P Brass
Journal:  Clin Investig (Lond)       Date:  2011-01-01

Review 4.  Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria.

Authors:  Kasia Stepniewska; Nicholas J White
Journal:  Malar J       Date:  2006-12-22       Impact factor: 2.979

5.  Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy.

Authors:  Marie T Aouad; Waseem S Alfahel; Roland N Kaddoum; Sahar M Siddik-Sayyid
Journal:  BMC Anesthesiol       Date:  2017-04-11       Impact factor: 2.217

6.  Noninferior Antibiotics: When Is "Not Bad" "Good Enough"?

Authors:  Mark J DiNubile
Journal:  Open Forum Infect Dis       Date:  2016-05-25       Impact factor: 3.835
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.